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An enzyme-responsive peptide drug conjugate was developed for TGX-D1, a promising PI3K inhibitor for prostate cancer therapy.
LNCaP-specific KYL peptide was used as the targeting ligand and the prostate specific antigen (PSA) cleavable peptide (SSKYQSL) was
used as the enzyme-responsive linker. SSKYQSL is cleaved by recombinant human PSA at 10–250 μg/mL. By contrast, the linker is stable
in the serum of prostate cancer patients with high PSA levels (N500 ng/mL), indicating that this linker can survive the systemic circulation in
prostate cancer patients but be cleaved in the tumor microenvironment. Cellular uptake of the peptide drug conjugate in prostate cancer cells
is improved by about nine times. Biodistribution study reveals significant tumor accumulation of the peptide drug conjugate in nude mice
bearing C4–2 tumor xenografts. Meanwhile, distribution of the conjugate in other major tissues is the same as the parent drug, indicating a
high specificity of the conjugate to prostate cancers in vivo.
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.
org/licenses/by-nc-nd/4.0/).
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remains the second-leading cause of death due to cancer inAmerican
men. While surgery and radiation are effective in prostate cancer
therapy at early stages,majority of the patients ultimately relapse and
develop advanced prostate cancer. Chemotherapy is still the
mainstay of treatment for recurrent prostate cancer, and a great
deal of effort has been made to discover novel molecules for
advanced prostate cancer.1,2 The phosphoinositide 3-kinases
(PI3Ks) signaling pathway is one of the most important pathways
in cancer, and a number of PI3K inhibitors are currently in preclinical
and clinical studies for various cancers.3–8 Specifically, the isoform
PI3K-p110β has been proven essential for prostate cancer
tumorigenesis and androgen-independent progression.9,10
TGX-221 is a novel, isoform-specific, and potent small molecule
inhibitor of PI3K-110β.11 It has been successfully used in animals toKun Cheng, PhD was supported by an American Cancer Society–Lee
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therapeutic applications of TGX-221 in prostate cancer are currently
not feasible because of its poor aqueous solubility and nonspecific
expression of PI3K-110β in various tissues. Therefore, it is critical to
improve TGX-221’s solubility and target-ability to prostate cancers.
We recently developed a derivative of TGX-221, TGX-D1, with
a functional group that can be used for peptide conjugation. We
conjugated a HER2-specific peptide to TGX-D1 and demonstrated
improved solubility as well as enhanced cellular uptake in HER-2
positive prostate cancer cells.13 In another study, we conducted a
whole-cell biopanning procedure using peptide phage display and
discovered an LNCaP-specific peptide, KYLAYPDSVHIW
(KYL). The KYL peptide exhibits high and specific affinity to
LNCaP cell, which is the most widely used cell line in prostate
cancer research. Moreover, the KYL peptide can deliver its cargo to
prostate cancer cells, indicating its great promise as a targeting
ligand for prostate cancer diagnosis and targeted drug delivery.14
In addition to actively target tumor tissues, a stimulus-responsive
system that can specifically release active agents in tumor
microenvironment may further increase the tumor-specific accumu-
lation and penetration of the drug.2,15 For example, prostate-specific
antigen (PSA) is serine protease that is highly expressed in prostatecess article under the CC BY-NC-ND license (http://creativecommons.org/
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prostate cancer contains a high level (50-500 μg/mL) of
enzymatically active PSA.17 Moreover, PSA is only enzymatically
active in the interstitial space of prostate tumors. By contrast, PSA in
the blood circulation is not active because of the presence of PSA
inhibitors.18,19 PSA-cleavable linker has therefore been utilized to
improve the efficacy of various targeted therapeutics in prostate
cancer.13,18,20,21
In this study, the LNCaP-specific peptide KYLAYPDSVHIW
is linked to TGX-D1 through a PSA-cleavable linker (SSKYQSL).
We examined the stability of the PSA-cleavable linker in
recombinant human PSA and the sera of prostate cancer patients.
We also investigated the cellular uptake, in vitro activity and
biodistribution of the peptide conjugated TGX-D1 in mice bearing
human prostate cancer xenografts.Methods
Materials
TGX-221 was purchased from Medkoo Biosciences (Chapel Hill,
NC).N,N-Diisopropylethylamine (DIPEA), 4-dimethyl-aminopyridine
(DMAP), trifluoroacetic acid (TFA), triethylamine, triisopropylsilane
(TIPS), HATU, and piperidine were ordered from Fisher
Scientific. Unidentified sera of prostate cancer patients were obtained
from BioServe Biotechnologies, Ltd. (Beltsville, MD), and recombi-
nant human PSAwas ordered from Lee Biosolutions (St. Louis, MO).
Amino acids were purchased from Anaspec (Fremont, CA). The
N-terminal of peptides is modified by acetyl group to increase peptide
stability.
Cleavage study of the PSA-cleavable peptide
The PSA-cleavable peptide Ac-SSKYQSL-NH2 was incubated
at a final concentration of 300μMat 37 °Cwith PBS, human serum,
serum from prostate cancer patient, and recombinant human PSA.
PSA levels in the sera from prostate cancer patients were measured
using a human PSA ELISA kit (R&D Systems Inc. Minneapolis).
Aliquots of 30 μL from each group were collected at various time
points (0, 1, 3 and 6 h) and incubated with 90 μL acetonitrile,
containing 0.1% TFA at room temperature. After incubation for
5 min, concentration of the intact Ac-SSKYQSL-NH2 in the
organic phase was determined using HPLC.
Synthesis of the peptide drug conjugate KYL-TGX
TGX-D1 and NH2-L-TGX-D1 were synthesized and purified as
we reported before. KYL-TGX was synthesized using a similar
method.13 Briefly, NH2-L-TGX-D1 (0.01 mmol) and the undepro-
tected peptide Ac-KYLAYPDSVHIWGGGSSKYQS (0.02 mmol)
dissolved in dried DMF were mixed with HATU and DIPEA at
room temperature for 12 h. The reaction was then stopped by
addition of saturated NH4Cl aqueous solution. After removal of the
solvent, the residue was reconstituted in 20 mL of chloroform,
washed with water, concentrated under vacuum, and purified using
silica gel column. After removing the protecting groups present in
the peptide moiety, the peptide drug conjugate KYL-TGX was
purified using reverse-phase HPLC and characterized with LC/MS.
Ac-KYLAYPDSVHIWGGGSSKYQSL-TGX-D1 (KYL-TGX):ESIMS calculated for C139H194N32O36 2909.433, found 969.5
(M + 3)3+, 1455.4 (M + 2)
2+.
Release of the parent drug from KYL-TGX
Release of the parent drug from KYL-TGX in the presence of
recombinant human PSA was evaluated as reported.13 Briefly,
KYL-TGX (100 μM) was incubated with 10 μg/mL human
recombinant PSA at 37 °C. Aliquots of 50 μL were collected at
different time intervals for analyzing using a Shimadzu HPLC
system (SIL-1QAF auto sampler, LC-2QAT controller pump,
SPD-1QA UV detector) on a C-18 reverse-phase column
(4.6 × 250 mm, 5 μm).
Cell cytotoxicity IC50
C4-2 cells were seeded in a 96-well plate at a density of
1 × 104 cells/well and incubated for 24 h before the study. The
cells were washed and incubated with KYL-TGX and TGX-D1
at 37 °C for 72 h. Cell viability was measured using MTT assay.
The IC50 values were calculated by fitting a concentration–
response curve using Graphpad Prism 5 (Graphpad Software,
Inc.).
Cellular uptake and toxicity study
C4-2 cells (3 × 105 cells/well) were seeded in 24-well plates
for 24 h and then incubated with KYL-TGX, dipeptide-TGX-D1
and TGX-D1 at 37 °C. After incubation for 1 h, the cells were
washed with PBS and then lysed as we described before.13 Drug
molecules were extracted from cell lysate using a liquid–liquid
extraction method.13 Both KYL-TGX and dipeptide-TGX-D1
were cleaved by NaOH to form TGX-D1 during the extraction
process. Concentrations of TGX-D1 in the cell lysate were
quantitated using LC–MS/MS. BCA protein assay kit (Pierce,
Rockford, IL) was used to quantitate the total protein
concentration of the cell lysate. Cellular uptake was normalized
to the total protein content of the samples.
PSA levels in the cell culture medium were also monitored.
Briefly, C4-2 cells were plated at a density of 3 × 105 cells/well
in 24-well plates for 24 h, followed by replacement with fresh
medium. After incubation for 1 h and 24 h, the medium
(supernatant) was collected for PSA assay using a human PSA
ELISA kit (R&D Systems Inc. Minneapolis).
Cellular cytotoxicity of KYL-TGX and TGX-D1 in C4-2
cells was compared after 1 h and 2 h incubation. Briefly, C4-2
cells (5 × 103 cells/well) seeded in 96-well plates were
incubated with KYL-TGX and TGX-D1 at 37 °C for 1 h and 2
h, followed by replacement with fresh medium. MTT assay was
conducted at 72 h post treatment to determine the cell viability.
Stability study of KYL-TGX in PBS and human serum
Stability of the peptide conjugated drug was studied in PBS
and human serum. The peptide drug conjugate KYL-TGX (5
μM) was incubated in PBS or 50% human serum at 37 °C. At
various time intervals, aliquots of 20 μL were mixed with 60 μL
acetonitrile containing 0.1% formic acid to precipitate serum
proteins. After centrifugation at 12,000 ×g for 10 min, 50 μL of
the supernatant was collected and analyzed using HPLC.
Figure 1. Synthesis scheme of KYL-TGX. Reaction conditions: (A) Methylbromoacetate, DIPEA, CH3CN; (B) LiCl, NaBH4, THF/EtOH (C) Fmoc-Leu, EDCI,
DMAP (cat), DCM; (D) DCM containing 20% piperidine; (E) HATU, NMP, DIPEA; (F) TFA/TIPS/DCM (47.5/5/47.5), room temperature.
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The animal protocol was approved by the University of
Missouri-Kansas City, Institutional Animal Care and Use
Committee (IACUC). Four- to five-week-old male nude mice
were housed in a temperature-controlled room with a 12 h light–
dark cycle. The C4-2 xenograft tumor model was developed by
subcutaneous injection of 3.5 × 106 cells with Matrigel into the
right and left flanks of each mouse. The tumors were allowed to
grow to a mean volume of 500 mm3, and then the mice were
randomly assigned into two groups for drug administration via
the tail vein. One group of the mice received 2 mg/kg TGX-D1,
and the second group received KYL-TGX at the equivalent dose
2 mg/kg TGX-D1. The mice were then sacrificed at various time
points ranging from 30 min to 12 h. Blood and major organs such
as the tumors, liver, heart, kidneys, lungs and spleen were
harvested, washed, blotted dried, weighed, and stored at −80 °C.
KYL-TGX and TGX-D1 were extracted from the tissues using a
liquid/liquid extraction protocol and then analyzed using LC–
MS/MS as we and others reported.13,22 During the extraction
process, KYL-TGX is converted to TGX-D1 by NaOH. As a
result, concentrations of TGX-D1 in the samples were
quantitated using LC–MS/MS. The detection limit of TGX-D1
is approximately 10 nM. TGX-221 was added as the internal
standard before extraction.Results
Synthesis of KYL-TGX
We previously synthesized a TGX-221 derivative, TGX-D1,
which contains a hydroxyl group to conjugate peptides. TGX-D1exhibits similar activity as TGX-221 in inhibiting androgen-induced
gene expression and cell proliferation. We also conjugated a
HER2-specific peptide to TGX-D1 and demonstrated increased
solubility and cellular uptake in prostate cancer cells.13 In this
study, we used similar approach to attach the LNCaP-specific
peptide KYL to TGX-D1 via a PSA-cleavable linker (Figure 1).
Fmoc protected Leucine was coupled to the –OH of TGX-D1
through an ester linker to form NH2-L-TGX. Undeprotected
peptides Ac-KYLAYPDSVHIWGGGSSKYQS including the
LNCaP-specific peptide, Gly-Gly-Gly, and the PSA-cleavable
linker were conjugated to NH2-L-TGX through an amide bond.
The N-terminal of the peptide was modified with acetyl group to
improve its stability. The undeprotected KYL-TGXwas deprotected
and then purified using HPLC.
Stability and cleavage study of the PSA-cleavable peptide
SSKYQSL
We hypothesize that the PSA-cleavable linker SSKYQSL can
only be cleaved by enzymatically active PSA in the interstitial space
of prostate tumors. It is therefore critical to evaluate its stability in
recombinant human PSA and the sera from prostate cancer patients.
We first studied the stability of Ac-SSKYQSL-NH2 in PBS
containing recombinant human PSA at various concentrations
(0, 0.1, 1, 10, 100 and 250 μg/mL). As Figure 2, A shows, the
PSA-cleavable substrate is stable up to 6 h when the PSA level is
less than 10 μg/mL in the PBS. However, at high PSA levels
(10-250 μg/mL), the substrate is steadily cleaved. In a similar study,
we evaluated the stability of Ac-SSKYQSL-NH2 in 50% human
serum supplemented with recombinant human PSA (Figure 2, B).
Similarly, the substrate is cleaved by PSA in a dose-dependent
manner. In the presence of 100 μg/mL recombinant PSA, the
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Figure 2. Cleavage study of the PSA-cleavable peptide Ac-SSKYQSL-NH2. (A) PBS supplemented with recombinant human PSA. (B) 50% human serum
supplemented with recombinant human PSA. (C) Sera from four unidentified prostate cancer patients. The PSA levels in the serum were measured using a
human PSA ELISA kit. The results are presented as mean ± SD (n = 3).
Figure 3. Release of the parent drug from KYL-TGX in the presence of
recombinant human PSA. The results are presented as mean ± SD (n = 3).
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50% serum decreases to 0.6 h and 0.5 h, respectively, in the presence
of 250 μg/mL recombinant PSA. These results demonstrate that the
PSA-cleavable linker can be efficiently cleaved in prostate tumor
interstitial space, which contains a substantial level (50-500 μg/mL)
of enzymatically active PSA.17
We next studied the stability of the PSA substrate
Ac-SSKYQSL-NH2 in the sera from four independent prostate
cancer patients. The PSA levels in the sera were measured using ahumanPSAELISAkit (R&DSystems Inc.Minneapolis, USA). The
serum PSA levels are 168, 3.74, 546.6, and 26.88 ng/mL for the
patient 1, 2, 3 and 4 respectively (Figure 2,C). As the stability assay
shows, the PSA substrate is quite stable in the sera from prostate
cancer patients evenwhen the PSA level is higher than 546 ng/mL in
the patient 3 (Fig. 2, C). These results from Figure 2 (A, B & C)
clearly suggest the PSA-cleavable substrate SSKYQSL is stable in
the blood of prostate cancer patients, but can be readily cleaved in the
tumor interstitial space, which contains a high concentration of
enzymatically active PSA.Release of the parent drug from KYL-TGX
We hypothesize that the peptide drug conjugate (KYL-TGX)
can be cleaved in the tumor microenvironment by PSA to release
the dipeptide drug (SL-TGX), which will be finally cleaved by
esterase to release the parent drug TGX-D1 in the cells to exert its
activity. The KYL-TGX was therefore incubated with human
recombinant PSA (10 μg/mL) at 37 °C for various time intervals.
The KYL-TGX, SL-TGX, and TGX-D1 were monitored using
HPLC as we reported.13 As Figure 3 illustrates, KYL-TGX is
steadily cleaved by PSA to release SL-TGX with a t1/2 of
approximately 8 h. We also observed a steady release of the
parent drug from SL-TGX, indicating that KYL-TGX can
efficiently release the active parent drug in prostate cancers.
Figure 4. Cell cytotoxicity IC50 of TGX-D1 (A) and KYL-TGX (B) in C4-2 cells. The results are presented as mean ± SD (n = 3).
Figure 5. Cellular uptake study of KYL-TGX, dipeptide-TGX-D1, and TGX-D1 in C4-2 cells. (A) PSA concentrations in the cell culture medium of C4-2 cells
after incubation with fresh medium for 1 and 24 h. (B) After incubation with the drug at 1 μM for 1 h, C4-2 cells were washed and lysed, followed by drug
quantitation using LC–MS/MS. Cellular uptake was normalized to the total amount of protein. The results are presented as mean ± SD (n = 3). (** P b 0.01).
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We next examined whether peptide modification affects the
cellular cytotoxicity IC50 of the drug in C4-2 cells. KYL-TGX
and TGX-D1 were incubated in C4-2 cells for 72 h, and MTT
assay was used to determine cell viability. As shown in Figure 4,
TGX-D1 and KYL-TGX induce similar cytotoxicity profile in
C4-2 cells. The IC50 values for TGX-D1 and KYL-TGX are
11.36 μM and 14.93 μM, respectively. These results suggest that
KYL-TGX can efficiently release the parent drug TGX-D1
inside cells to exhibit its activity.
Cellular uptake of KYL-TGX
In order to study whether the LNCaP-specific peptide KYL
can enhance the delivery of the KYL-TGX to prostate cancers,
we performed cellular uptake study in C4-2, which is a derivative
cell line of LNCaP. KYL-TGX, dipeptide-TGX-D1 and
TGX-D1 were incubated with C4-2 cells at 1 μM for 1 h. As
Figure 5, B shows, compared to TGX-D1, KYL-TGX exhibits
nearly nine-fold higher uptake in the cells, demonstrating that
coupling of the LNCaP-specific peptide KYL dramatically
enhances the delivery of its cargo to prostate cancer cells.
Moreover, dipeptide-TGX-D1 shows 2-fold higher uptake
compared to TGX-D1, indicating that the dipeptide transporter
in prostate cancer cells can be utilized to enhance drug delivery.
The PSA concentration in the cell culture medium was also
determined (Figure 5, A). After 1 h incubation of C4-2 cells with
fresh medium, the PSA level in the medium is about 2.88 ng/mL.The PSA level increases to 20.13 ng/mL after 24 h incubation.
As shown above in Figure 2, A, the PSA-cleavable linker is
stable in the presence of PSA up to 1 μg/ml. Therefore, the PSA
in the cell culture medium is not high enough to degrade
KYL-TGX during the cellular uptake study.
We further studied whether the enhancement in cellular uptake
is correlated with its activity. C4-2 cells were incubated with 1 μM
of TGX-D1 and KYL-TGX for 1 h and 2 h, followed by
replacement with fresh medium and MTT assay at 72 h post
treatment. As Figure 6 illustrates KYL-TGX exhibit higher activity
than TGX-D1 at both incubation time intervals, indicating the
enhanced cellular uptake and activity of KYL-TGX.
Serum stability of peptide drug conjugate KYL-TGX
Stability of KYL-TGX in 50% human serum and PBS was
assayed at 37 °C. As shown in Figure 7, KYL-TGX is generally
stable in PBS. After 4 h incubation in PBS, only about 6% of
KYL-TGX is degraded. By comparison, KYL-TGX exhibits a
time dependent degradation in human serum with a t1/2 of 3.5 h,
and approximately 58% of KYL-TGX is degraded after 4 h. This
result is in consistent with our previous finding from the HER2
peptide modified TGX-D1.13 The degradation is possible due to
the cleavage of the ester linker between the peptide and TGX-D1.
Biodistribution and pharmacokinetic study
Biodistribution and pharmacokinetics of KYL-TGX and
TGX-D1 were studied in nude mice bearing human prostate
Figure 6. Cytotoxicity of KYL-TGX and TGX-D1 in C4-2 cells after 1 and 2 h incubation. C4-2 cells were incubated with 1 μM TGX-D1 and KYL-TGX for 1
and 2 h, followed by replacement with fresh medium and MTT assay at 72 h post treatment. The results are presented as mean ± SD (n = 3). (*P b 0.05;
**P b 0.01).
Figure 7. Stability of the KYL-TGX in human serum and PBS. KYL-TGX
was incubated in PBS (pH 7.5) and 50% human serum at 37 °C for various
time intervals. The remaining KYL-TGX was analyzed using HPLC. The
results are presented as mean ± SD (n = 3).
Table 1
Pharmacokinetic parameters of KYL-TGX and TGX-D1 in nude mice
bearing C4-2 tumor xenografts.
PK Parameter KYL-TGX TGX-D1
t1/2α (h) 0.13 ± 0.11 0.03 ± 0.03
t1/2β (h) 0.77 ± 0.38 0.64 ± 0.16
Vd (mL) 1.50 ± 001 1.50 ± 001
CL (mL/h) 3.05 ± 0.35 3.14 ± 0.39
AUC 0-inf (μg/mL*h) 16.49 ± 1.78 16.03 ± 1.89
MRT (h) 0.81 ± 0.15 0.89 ± 0.24
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concentrations in the plasma, tumor, liver, kidneys, lungs, and
spleen were measured using LC–MS/MS. The plasma concen-
tration data were fitted using a two-compartment model, and
pharmacokinetic parameters of KYL-TGX and TGX-D1 were
summarized in Table 1. Both KYL-TGX and TGX-D1 exhibit a
biphasic plasma elimination profile with similar distribution
half-life (t1/2α), elimination half-life (t1/2β), volume of distribu-
tion (Vd), clearance, area under the curve (AUC), and mean
residence time (MRT).
Biodistribution of KYL-TGX and TGX-D1 in the plasma,
tumor, liver, kidneys, lungs, and spleen is presented in Figure 8.
Following intravenous administration, both of them exhibit similar
and rapid kidney elimination due to their small molecular weight.
In addition, KYL-TGX and TGX-D1 exhibit nearly the same
distribution profiles in the liver, spleen, and lungs. By contrast,drug concentration of KYL-TGX in the tumor is significantly
higher than that of TGX-D1 at all the time intervals (Figure 8, A).
The tumor area under the curve (AUC0-24h) of KYL-TGX is
approximately 3.2-fold greater than that of TGX-D1 (Figure 8, B).
These results clearly indicate a high and specific affinity of the
KYL-TGX to prostate cancer cells in vivo.Discussions
Despite continuous efforts and advancements, chemotherapy
is still the most extensively adopted approach for advanced
prostate cancer. Therapeutic effect of chemotherapy is however
limited because of nonspecificity, inadequate availability to
tumors, and the complicated microenvironment in tumor sites.1
It is therefore critical to improve the targetability and tumor
penetration of chemotherapy agents. A variety of targeting
ligands such as antibodies, aptamers, and peptides have been
explored to specifically deliver therapeutics to prostate cancer
cells via active targeting mechanisms.2 Compared to other types
of ligands, peptide ligands exhibit many advantages including
low molecular weight, ease of synthesis, better cellular
permeability, low immunogenicity, flexibility in chemical
conjugation, and high drug loading capacity.23 We recently
discovered an LNCaP-specific peptide (KYLAYPDSVHIW,
KYL), which can specifically deliver its cargo to LNCaP cells.24
Figure 8. Biodistribution of KYL-TGX and TGX-D1 in nude mice bearing C4-2 tumor xenografts. The drug was administered at 2 mg/kg via the tail vein. At 0.5,
1, 3, 6, and 12 h post administration, the blood and major organs including the tumors, liver, heart, kidneys, lungs and spleen were harvested, washed, blotted
dried, and weighed. Drug molecules were extracted from these samples using a liquid/liquid extraction procedure. Drug concentrations were determined using
LC–MS/MS and normalized to the total protein content of the samples. (A) Biodistribution of KYL-TGX and TGX-D1 in the plasma, liver, kidneys, spleen,
lungs, and tumor. (B) Tumor area under the curve (AUC) of KYL-TGX and TGX-D1 (*P b 0.05; **P b 0.01). The results are presented as mean ± SD (n = 3).
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platform to improve the efficacy of chemotherapy agents.13,23,25 Its
small size leads to excellent cell permeability, better tumor
penetration, and high drug-loading capability. Moreover,
peptide drug conjugate can significantly improve the aqueous
solubility of parent drug if the peptide moiety is hydrophilic.13 We
have recently synthesized a TGX-221 derivative, TGX-D1, which
contains a hydroxyl group for peptide conjugation and exhibits
similar activity and isoform-specificity as TGX-221.13 In this study,
we conjugated the LNCaP-specific peptide KYL to TGX-D1, a
PI3K-p110β inhibitor, through a PSA-cleavable linker.
We recently discovered that dipeptide transporters are over-
expressed in prostate cancer cells.26 We also demonstrated that
dipeptide linked drug shows higher cellular uptake than unmodified
drug in prostate cancer cells, suggesting that peptide transporters in
prostate cancers can be utilized to enhance the cellular uptake and
tumor penetration of dipeptide linked drug.13 We therefore include
a dipeptide SL between the PSA-cleavage site and the parent drug
(Figure 1). We hypothesize that the KYL ligand can specifically
deliver the peptide drug conjugate KYL-TGX to prostate cancers.
The PSA substrate will be cleaved by PSA in the tumor interstitial
space, and the released dipeptide-linked TGX will diffuse into
tumor cells via overexpressed dipeptide transporters in prostate
cancer cells, thus enhancing tumor penetration.
PSA is a serine protease that is highly expressed in prostate
cancers rather than other normal tissues.2,16 The serum PSA
level in prostate cancer patients is much lower than the PSA level
in tumor interstitial space (extracellular fluid). For example, one
study investigated the serum PSA levels in patients with newly
diagnosed prostate cancer. The mean PSA value for 133 African
Americans was 14 ng/mL compared with 8.29 ng/mL for 408
white men.27 In studies where bone scans are positive for
prostate cancer metastasis, the serum PSA levels have averaged
between 30.0 and 140.0 ng/mL.28–31 By contrast, the interstitial
space of prostate cancer contains a high level of enzymaticallyactive PSA in the range of 50-500 μg/mL,17 which is about a
thousand-fold greater than the serum PSA level in prostate cancer
patients. Moreover, PSA is only enzymatically active in the
interstitial space of prostate tumors. By contrast, PSA in the blood
circulation is not active because of the presence of PSA
inhibitors.18,19,32 Consequently, PSA-cleavable substrate is stable
in the blood circulation but can be cleaved in the interstitial space of
prostate tumors to release the active drug.
We evaluated the cleavage efficacy of the PSA substrate
SSKYQSL in PBS or 50% human serum supplemented with
recombinant human PSA. As shown in Figure 2, the PSA
substrate can be cleaved by recombinant human PSA when the
concentration is higher than 1 μg/mL, suggesting that it can be
efficiently cleaved in prostate cancer interstitial space, where the
concentration of PSA is in the range of 50-500 μg/mL.
To prove that the PSA substrate is stable in the blood circulation
of prostate cancer patients, we performed the stability assay of the
substrate in the sera from four unidentified prostate cancer patients.
The PSA levels in these patients are in the range of 3.74 to 546.6 ng/
mL. The PSA substrate exhibits good stability in all the four serum
samples (Figure 2, C). This is the first evidence showing that the
PSA-cleavable peptide SSKYQSL is stable in the serum from
prostate cancer patients regardless of the relatively high PSA levels
in the blood. These results clearly demonstrate that the
PSA-cleavable linker can be used to specifically release the active
drug in prostate cancer interstitial space.
LNCaP-specific peptide (KYL) is adopted as the targeting
moiety in the peptide drug conjugate to enhance cellular uptake in
prostate cancer cells. LNCaP is an androgen-sensitive human
prostate adenocarcinoma cell line and the most extensively used
cell line prostate cancer studies.33–35 Compared to other cell lines,
the progression model of LNCaP exhibits more similarities with
human prostate cancer. LNCaP cells express many key prostate
cancer biomarkers, such as PSMA, PSA, and PAP.36 It is worth
noting that although LNCaP is one of themostwidely used prostate
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prostate cancer. For other types of prostate cancers, wemay need to
replace the LNCaP-specific ligand. C4-2 is a subline of LNCaP,
and the KYL peptide also has a high affinity to C4-2 cells. Cellular
uptake study (Figure 5, B) demonstrates that the KYL peptide
dramatically increases the uptake of KYL-TGX in C4-2 cells.
Accordingly, KYL-TGX exhibits higher activity compared to
TGX-D1 in C4-2 cells (Figure 6).
We finally performed biodistribution and pharmacokinetic
studies in nude mice bearing C4-2 xenografts (Figure 8).
Compared to TGX-D1, KYL-TGX shows approximately
3.2-fold increase in tumor accumulation but similar uptake in
other organs including the plasma, liver, kidneys, spleen, and
lungs. This result clearly reveals the high specificity and affinity of
the KYL-TGX to prostate cancer cells in vivo. On the other hand,
KYL-TGX and TGX-D1 exhibit very similar distribution and
elimination rates. This could be mainly due to the small molecular
weight of KYL-TGX (Mw 2909) and TGX-D1 (Mw 409). Another
possible reason could be the cleavage of the ester bond between
TGX-D1 and the attached peptide. As shown in Figure 7, half-life
of the KYL-TGX in human serum is approximately 3.5 h, which is
mainly because of the cleavage of the ester bond. This is consistent
with our and others' reports.13,37 Moreover, the esterase activity in
mouse serum is about 10 times higher than in human serum.38
Therefore, some of the administered KYL-TGX could be degraded
in the blood circulation by esterase before they can reach prostate
cancer cells. This result suggests that replacement of the ester bond
with a more stable linker, such as an amide or disulfide bond, may
further increase the tumor accumulation of KYL-TGX in vivo.
In summary, an enzyme-responsive peptide drug conjugate
KYL-TGX consisting of the LNCaP-specific peptide KYL,
PSA-cleavable linker, and TGX-D1 was synthesized. We demon-
strated for the first time that the PSA-cleavable peptide SSKYQSL is
stable in the serum from prostate cancer patients but can be cleaved
in prostate cancer interstitial space. Biodistribution study in mouse
bearing tumor xenograft reveals high and specific accumulation of
KYL-TGX in tumors. These findings indicate that peptide drug
conjugate is a relatively simple but promising nanoscale platform for
prostate cancer chemotherapy agents.References
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